NDRA - エンドラ・ライフ・サイエンシズ （ENDRA Life Sciences Inc.） エンドラ・ライフ・サイエンシズNDRAのチャート
NDRAの企業情報
| symbol | NDRA |
|---|---|
| 会社名 | ENDRA Life Sciences Inc （エンドラ・ライフ・サイエンシズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Electromedical_Electrotherapeutic Apparatus |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ENDRA Life Sciences Inc. is engaged in commercialization of an enhanced ultrasound technology for the pre-clinical research market. The Company's Nexus 128 system combines light-based thermoacoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. The Company is involved in developing TAEUS for incorporation into new ultrasound systems. The TAEUS platform has capabilities and potential clinical applications such as enabling ultrasound to distinguish fat from lean tissue; enabling traditional ultrasound to visualize changes in tissue temperature in real time; enabling ultrasound to view blood vessels from any angle using only a saline solution contrasting agent unlike Doppler ultrasound which requires precise viewing angles and enabling ultrasound to image blood flow at the capillary level in a region organ or tissue. エンドラ・ライフ・サイエンシズは米国の医療機器メ―カ―。主に超音波技術の開発に従事する。同社の「Nexus 128」は、光音響画像と超音波を組み合わせた3D断層撮影装置で、臨床前研究において使用される。また、開発中の「TAEUS」は、熱音響を利用した超音波システムで、さまざまな病状の診断や治療に活用できる。本社はミシガン州アナ―バ―。 ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with the over 1 million ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. |
| 本社所在地 | 3600 Green Court Suite 350 Ann Arbor MI 48105-1570 USA |
| 代表者氏名 | Francois Michelon フランソワミッシェロン |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 734-335-0468 |
| 設立年月日 | 39264 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2017年 |
| 従業員数 | 13人 |
| url | www.endrainc.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ndra |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -7.80746 |
| 終値（lastsale） | 2.8694 |
| 時価総額（marketcap） | 11256733.6738 |
| 時価総額 | 時価総額（百万ドル） 11.06294 |
| 売上高 | 売上高（百万ドル） 0.30002 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 9.21066 |
| 当期純利益 | 当期純利益（百万ドル） -7.87562 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 ENDRA Life Sciences Inc revenues decreased 89% to $6K. Net loss increased from $2.2M to $4.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase from $271K to $2.5M (expense) Selling/General/Admin. Expense increase of 75% to $2M (expense). |
NDRAのテクニカル分析
NDRAのニュース
As The Stock Falls By -58.51% Year-To-Date, ENDRA Life Sciences Inc. (NASDAQ: NDRA)’S Stock Continues To Progress In 2022 2022/08/27 12:30:00 Marketing Sentinel
During the last session, ENDRA Life Sciences Inc. (NASDAQ:NDRA)’s traded shares were 0.4 million, with the beta value of the company hitting 1.37. At the end of the trading day, the stock’s price was $0.29, reflecting an intraday loss of -5.09% or -$0.01. The 52-week high for the NDRA share is $2.09, that puts it … As The Stock Falls By -58.51% Year-To-Date, ENDRA Life Sciences Inc. (NASDAQ: NDRA)’S Stock Continues To Progress In 2022 Read More »
ENDRA Life Sciences receives European patent for TAEUS system 2022/08/24 13:17:32 Seeking Alpha
ENDRA Life Sciences (NDRA) said on Wednesday the European Patent Office had issued Patent for its TAEUS system to calculate fat concentration in the human body with multiple…
ENDRA Life Sciences Announces Issuance of 8th European Patent for its TAEUS® System 2022/08/24 12:40:00 Business Wire
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the European Patent Office has issued European Patent No. 3730041 (the ‘041 patent) to ENDRA titled “System for Estimating Fractional Fat Content of an Object.” The ‘041 patent protects ENDRA''s TAEUS system for the calculation of fat concentration in the human body with multiple thermoacoustic measurements. The ‘041 patent
ENDRA Life Sciences Announces Issuance of 8th European Patent for its TAEUS System 2022/08/24 12:40:00 Wallstreet:Online
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS), announces that the European Patent Office has issued European Patent No. 3730041 (the ‘041 patent) to ENDRA titled “System for Estimating Fractional Fat Content of an Object.” The ‘041 patent protects ENDRA''s TAEUS system for the calculation of fat concentration in
ENDRA Life Sciences: Q2 Earnings Insights 2022/08/16 03:19:58 Benzinga
ENDRA Life Sciences (NASDAQ: NDRA ) reported its Q2 earnings results on Monday, August 15, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings ENDRA Life Sciences missed estimated earnings by 20.0%, … Full story available on Benzinga.com
ENDRA Life Sciences rises on new U.S. patent for liver disease monitoring system 2022/06/28 12:45:09 Seeking Alpha
ENDRA Life Sciences (NDRA) is trading 10% higher premarket after the United States Patent and Trademark Office issued a new patent for its Taeus’ radiofrequency ((RF)) applicator…
ENDRA Life Sciences Enhances TAEUS® System Intellectual Property Portfolio with Issuance of 28th U.S. Patent 2022/06/28 12:00:00 Business Wire
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NAFLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued a new ENDRA patent, U.S. Patent No. 11369272 (the ‘272 patent) titled “Broadband Applicator for Thermoacoustic Signal Generation.” The ‘272 patent protects TAEUS’ radiofrequency (RF) applicator for optimizing the delivery of RF energy to tissue. Notably, the RF applicator utilizes a broad ba
ENDRA Life Sciences Enhances TAEUS System Intellectual Property Portfolio with Issuance of 28th U.S. Patent 2022/06/28 12:00:00 Wallstreet:Online
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS), announces that the United States Patent and Trademark Office has issued a new ENDRA patent, U.S. Patent No. 11369272 (the ‘272 patent) titled “Broadband Applicator for Thermoacoustic Signal Generation.” The ‘272 patent protects TAEUS’ radiofrequency (RF) applicator for optimizing the delivery
ENDRA Life Sciences to Participate in the JMP Securities Life Sciences Conference 2022/06/08 12:00:00 Business Wire
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NAFLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, today announced that management will be participating in the JMP Securities Life Sciences Conference being held June 15-16, 2022 in New York City. Management will present a company overview on Wednesday, June 15th at 2:30 p.m. Eastern time and will host one-on-one meetings with investors. To request a meeting, please contact JMP Securities or Yvonne Briggs of LHA at ybriggs
Investment - Zacks: Analysts Expect ENDRA Life Sciences Inc. Will Post Earnings of -$0.05 Per Share 2022/06/04 10:07:26 Business Mag
Equities analysts predict that ENDRA Life Sciences Inc. will announce earnings per share of for the current fiscal quarter, Zacks Investment Research reports. Zero analysts…
ENDRA Life Sciences to Report First Quarter 2022 Financial Results on May 12, 2022 2022/05/02 12:00:00 Business Wire
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NAFLD--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the first quarter of 2022 on Thursday, May 12, 2022 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions. Partici
ENDRA Life Sciences Inc. (NASDAQ: NDRA) Stock Seems Like A Good Option 2022/04/22 12:00:00 Stocks Register
ENDRA Life Sciences Inc. (NASDAQ:NDRA) shares, rose in value on Thursday, April 21, with the stock price up by 1.59% to the previous day’s close as strong demand from buyers drove the stock to $0.27. Actively observing the price movement in the last trading, the stock closed the session at $0.26, falling within a range … ENDRA Life Sciences Inc. (NASDAQ: NDRA) Stock Seems Like A Good Option Read More »
Endra Life Sciences raises $8.7M YTD from common stock sale through ATM equity facility 2022/04/21 13:08:17 Seeking Alpha
Endra Life Sciences raised $8.7M year-to-date from the sale of common stock through its at the market, or ATM, equity facility.
Thinking about buying stock in ENDRA Life Sciences, SeaChange, Protalix Biotherapeutics, Dingdong, or BigBear.ai? 2022/04/08 13:31:00 Benzinga
NEW YORK , April 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NDRA, SEAC, PLX, DDL, and BBAI. … Full story available on Benzinga.com
16 Stocks Moving in Friday''s Pre-Market Session 2022/04/08 11:11:38 Benzinga
Gainers Biofrontera Inc. (NASDAQ: BFRI ) rose 34.5% to $5.44 in pre-market trading. ENDRA Life Sciences Inc. (NASDAQ: NDRA ) rose 31.9% to $0.5891 in pre-market trading after gaining over 10% on Thursday. HC Wainwright & Co. maintained ENDRA Life Sciences with a Buy and lowered the price target from $6 to $5. MedAvail Holdings, Inc. (NASDAQ: MDVL ) rose 29.1% to $1.82 in pre-market trading. MedAvail shares jumped 64% on Thursday after Ally Bridge Group reported in a Form4 filing a purchase of roughly 21.176 million shares of MedAvail Holdings for an average price of $1.06 per share. Sunshine Biopharma, Inc. (NASDAQ: SBFM ) shares rose 20.7% to $11.65 in pre-market trading after surging 53% on Thursday. Aterian, Inc. (NASDAQ: … Full story available on Benzinga.com